RESUMO
Gemfibrozil, a lipid lowering agent, was administered to two patients with familial hyperlipidaemia and one patient with insulin dependent diabetes mellitus. It was partially effective in familial hyperlipidaemia. It dramatically reduced triglyceride and cholesterol levels in the patient with Type V hyperlipidaemia and insulin dependent diabetes mellitus. Patients with familial and Type V hyperlipidaemias should be given a trial of gemfibrozil therapy.
Assuntos
Adulto , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Feminino , Genfibrozila/uso terapêutico , Humanos , Hiperlipidemia Familiar Combinada/tratamento farmacológico , Hiperlipidemias , Doenças Vasculares/complicaçõesRESUMO
The efficacy of Gemfibrozil on S. lipid levels was studied in 36 middle aged subjects with type IIA, IIB, IV hyperlipidemia. Gemfibrozil was well tolerated in the dose of 1200 mg/day and no dropouts were attributable to its use. An overall reduction in total cholesterol (39.91%), total triglycerides (71.10%), VLDL triglycerides (62.97%). LDL cholesterol (45.57%) and apolipoprotein B levels (26.83%) were observed at 24 weeks. At the same time HDL cholesterol, and apolipoprotein A levels showed increases by 26.23% and 53.67% respectively. It is concluded that Gemfibrozil is an effective lipid lowering agent. Further long term studies are necessary to determine its optimal dosage and its long term safety in Indian subjects.
Assuntos
Adulto , Apolipoproteínas A/sangue , Apolipoproteínas B/sangue , Colesterol/sangue , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Avaliação de Medicamentos , Feminino , Genfibrozila/uso terapêutico , Humanos , Hiperlipidemias/sangue , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Triglicerídeos/sangueRESUMO
An unusual case of right atrial myxoma who had a ten year symptom free interval, following the initial manifestation is presented.